Generic Name and Formulations:
Temazepam 7.5mg, 15mg, 22.5mg, 30mg; caps.
Indications for RESTORIL:
Short-term (7–10 days) treatment of insomnia.
Use lowest effective dose. Usual dose: 7.5mg–30mg at bedtime. Elderly or debilitated: initially 7.5mg. Max 1 month/℞.
<18yrs: not established.
Risks from concomitant use with opioids.
Risks from concomitant use with opioids (see Interactions). Suicidal tendencies. Depression. Pulmonary, renal, or hepatic impairment. Drug or alcohol abuse. Reevaluate if used ≥2 weeks. Sleep disturbances after stopping drug. Avoid abrupt cessation after prolonged use. Elderly. Nursing mothers.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants.
Drowsiness, headache, fatigue, nervousness, lethargy, dizziness, hangover, confusion, weakness, paradoxical excitement, euphoria; sleep-driving and other complex behaviors (eg, preparing/eating food), anaphylaxis, angioedema.
Caps 7.5mg—30, 100; 22.5mg—30; 15mg, 30mg—100
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness